These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

781 related articles for article (PubMed ID: 33346905)

  • 1. The role of the gut microbiome and its metabolites in metabolic diseases.
    Wu J; Wang K; Wang X; Pang Y; Jiang C
    Protein Cell; 2021 May; 12(5):360-373. PubMed ID: 33346905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The intestinal microbiome and metabolic diseases : From obesity to diabetes and nonalcoholic steatohepatitis].
    Bischoff SC
    Internist (Berl); 2017 May; 58(5):441-448. PubMed ID: 28432400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disruptions in gut microbial-host co-metabolism and the development of metabolic disorders.
    Rajani C; Jia W
    Clin Sci (Lond); 2018 Apr; 132(7):791-811. PubMed ID: 29661926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification.
    Panasevich MR; Peppler WT; Oerther DB; Wright DC; Rector RS
    Physiol Genomics; 2017 Aug; 49(8):385-399. PubMed ID: 28600319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut Microbiota as a Therapeutic Target for Metabolic Disorders.
    Okubo H; Nakatsu Y; Kushiyama A; Yamamotoya T; Matsunaga Y; Inoue MK; Fujishiro M; Sakoda H; Ohno H; Yoneda M; Ono H; Asano T
    Curr Med Chem; 2018; 25(9):984-1001. PubMed ID: 28990516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut microbial metabolites in obesity, NAFLD and T2DM.
    Canfora EE; Meex RCR; Venema K; Blaak EE
    Nat Rev Endocrinol; 2019 May; 15(5):261-273. PubMed ID: 30670819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications.
    Jayakumar S; Loomba R
    Aliment Pharmacol Ther; 2019 Jul; 50(2):144-158. PubMed ID: 31149745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Metabolic Role of Gut Microbiota in the Development of Nonalcoholic Fatty Liver Disease and Cardiovascular Disease.
    Sanduzzi Zamparelli M; Compare D; Coccoli P; Rocco A; Nardone OM; Marrone G; Gasbarrini A; Grieco A; Nardone G; Miele L
    Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27483246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Obesity and Obesity-Associated Metabolic Disorders: Current Evidence and Perspectives.
    Vallianou N; Stratigou T; Christodoulatos GS; Dalamaga M
    Curr Obes Rep; 2019 Sep; 8(3):317-332. PubMed ID: 31175629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function.
    Sharpton SR; Ajmera V; Loomba R
    Clin Gastroenterol Hepatol; 2019 Jan; 17(2):296-306. PubMed ID: 30196156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between gut microbiome and cardiovascular disease.
    Peng J; Xiao X; Hu M; Zhang X
    Life Sci; 2018 Dec; 214():153-157. PubMed ID: 30385177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut microbiota, obesity and metabolic disorders.
    Federico A; Dallio M; DI Sarno R; Giorgio V; Miele L
    Minerva Gastroenterol Dietol; 2017 Dec; 63(4):337-344. PubMed ID: 28927249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders.
    Aron-Wisnewsky J; Vigliotti C; Witjes J; Le P; Holleboom AG; Verheij J; Nieuwdorp M; Clément K
    Nat Rev Gastroenterol Hepatol; 2020 May; 17(5):279-297. PubMed ID: 32152478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Gut Microbiota on Obesity, Diabetes, and Cardiovascular Disease Risk.
    Miele L; Giorgio V; Alberelli MA; De Candia E; Gasbarrini A; Grieco A
    Curr Cardiol Rep; 2015 Dec; 17(12):120. PubMed ID: 26497040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of gut microbial metabolites in nonalcoholic fatty liver disease.
    Zhao ZH; Lai JK; Qiao L; Fan JG
    J Dig Dis; 2019 Apr; 20(4):181-188. PubMed ID: 30706694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions between Gut Microbiota and Natural Bioactive Polysaccharides in Metabolic Diseases: Review.
    Pi Y; Fang M; Li Y; Cai L; Han R; Sun W; Jiang X; Chen L; Du J; Zhu Z; Li X
    Nutrients; 2024 Aug; 16(17):. PubMed ID: 39275156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut microbiota and its metabolic potential.
    Czajkowska A; Kaźmierczak-Siedlecka K; Jamioł-Milc D; Gutowska I; Skonieczna-Żydecka K
    Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12971-12977. PubMed ID: 33378048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease.
    Jennison E; Byrne CD
    Clin Mol Hepatol; 2021 Jan; 27(1):22-43. PubMed ID: 33291863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microbiota and Aging.
    Lu M; Wang Z
    Adv Exp Med Biol; 2018; 1086():141-156. PubMed ID: 30232757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.
    Kirpich IA; Marsano LS; McClain CJ
    Clin Biochem; 2015 Sep; 48(13-14):923-30. PubMed ID: 26151226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.